|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: C1orf226 |
Gene summary for C1ORF226 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | C1orf226 | Gene ID | 400793 |
| Gene name | chromosome 1 open reading frame 226 | |
| Gene Alias | C1orf226 | |
| Cytomap | 1q23.3 | |
| Gene Type | protein-coding | GO ID | NA | UniProtAcc | A1L170 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 400793 | C1orf226 | HTA11_2487_2000001011 | Human | Colorectum | SER | 9.95e-05 | 1.11e-01 | -0.1808 |
| 400793 | C1orf226 | HTA11_1938_2000001011 | Human | Colorectum | AD | 6.65e-03 | 1.12e-01 | -0.0811 |
| 400793 | C1orf226 | HTA11_347_2000001011 | Human | Colorectum | AD | 5.55e-12 | 1.40e-01 | -0.1954 |
| 400793 | C1orf226 | HTA11_83_2000001011 | Human | Colorectum | SER | 1.18e-03 | 1.76e-01 | -0.1526 |
| 400793 | C1orf226 | HTA11_696_2000001011 | Human | Colorectum | AD | 7.17e-13 | 1.16e-01 | -0.1464 |
| 400793 | C1orf226 | HTA11_1391_2000001011 | Human | Colorectum | AD | 2.34e-02 | 1.41e-01 | -0.059 |
| 400793 | C1orf226 | HTA11_5212_2000001011 | Human | Colorectum | AD | 8.89e-03 | 3.27e-01 | -0.2061 |
| 400793 | C1orf226 | HTA11_7663_2000001011 | Human | Colorectum | SER | 5.47e-03 | 2.16e-01 | 0.0131 |
| 400793 | C1orf226 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 9.79e-06 | 8.43e-02 | 0.294 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| C1orf226 | SNV | Missense_Mutation | novel | c.436N>C | p.Glu146Gln | p.E146Q | A1L170 | protein_coding | tolerated(0.18) | possibly_damaging(0.628) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| C1orf226 | SNV | Missense_Mutation | rs190618621 | c.649G>A | p.Ala217Thr | p.A217T | A1L170 | protein_coding | tolerated(0.57) | benign(0) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| C1orf226 | SNV | Missense_Mutation | novel | c.197N>G | p.Ser66Cys | p.S66C | A1L170 | protein_coding | deleterious(0) | probably_damaging(0.98) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
| C1orf226 | SNV | Missense_Mutation | c.856N>A | p.Glu286Lys | p.E286K | A1L170 | protein_coding | deleterious(0.01) | possibly_damaging(0.558) | TCGA-IR-A3LH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| C1orf226 | SNV | Missense_Mutation | novel | c.562C>A | p.Leu188Ile | p.L188I | A1L170 | protein_coding | deleterious(0.03) | benign(0.422) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| C1orf226 | SNV | Missense_Mutation | c.791N>T | p.Ala264Val | p.A264V | A1L170 | protein_coding | tolerated(0.14) | benign(0.116) | TCGA-F4-6570-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| C1orf226 | SNV | Missense_Mutation | c.542T>C | p.Leu181Pro | p.L181P | A1L170 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-AG-3892-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| C1orf226 | SNV | Missense_Mutation | c.233N>G | p.Ser78Cys | p.S78C | A1L170 | protein_coding | deleterious(0.03) | possibly_damaging(0.789) | TCGA-AG-A026-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| C1orf226 | SNV | Missense_Mutation | c.173C>T | p.Ala58Val | p.A58V | A1L170 | protein_coding | tolerated(0.29) | benign(0.124) | TCGA-EI-6507-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| C1orf226 | SNV | Missense_Mutation | novel | c.445N>G | p.Arg149Gly | p.R149G | A1L170 | protein_coding | tolerated(0.41) | benign(0.02) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |